Form 424B5 4D Molecular Therapeutic

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Form 424B5 4D Molecular Therapeutic

Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'

February 7, 2024 4:53 AM EST

(Updated - February 7, 2024 5:21 AM EST)

Goldman Sachs analyst Salveen Richter reinstates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target of $81.00.

The analyst comments "Given positive Ph2 intravitreal gene therapy 4D-150 data in wet age-related macular degeneration (wAMD), and the planned Ph3 initiation in 1Q25, we move from Not... More